Mitophagy in Hypertensive Cardiac Hypertrophy: Understanding the Dual Role of Cellular Process in Cardiovascular Disease

Research published in The Journal of Clinical Hypertension has shed light on the complex mechanisms underlying hypertensive cardiac hypertrophy (HCH), a condition that can lead to heart failure if left unmanaged. The study, conducted by researchers at the Second Medical Center of Chinese PLA General Hospital, reveals that mitophagy, a selective autophagic process, plays a critical role in HCH pathogenesis. Mitophagy's dual nature, with both protective and detrimental effects, presents a therapeutic paradox demanding contextual modulation.

Key Takeaways:

• Mitophagy is a critical process in hypertensive cardiac hypertrophy (HCH) pathogenesis, with impaired mitophagy leading to cardiomyocyte death, oxidative stress, and fibrosis.
• The dual nature of mitophagy presents a therapeutic paradox, with both protective and detrimental effects contributing to disease progression.
• The study highlights the importance of understanding the molecular mechanisms underlying mitophagy dysregulation in HCH, including the key pathways of PINK1/Parkin, BNIP3/NIX, and FUNDC1.
• Mitophagy dysregulation is linked to other cellular processes, including mitochondrial biogenesis, inflammasome activation, and metabolic remodeling.
• Potential therapeutic strategies targeting mitophagy to ameliorate HCH include pharmacological agents, lifestyle interventions, and gene therapy approaches.

Statistics:

• HCH affects approximately 30% of individuals with hypertension, leading to heart failure in 10-20% of cases (Tidhar et al., 2018).
• Mitophagy plays a critical role in HCH pathogenesis, with impaired mitophagy contributing to cardiomyocyte death, oxidative stress, and fibrosis (Ling et al., 2019).
• The PINK1/Parkin pathway is a significant regulator of mitophagy in HCH, with impaired PINK1/Parkin function leading to reduced mitophagy and increased oxidative stress (Cao et al., 2020).

Sources:

• NewsRx. Researchers at Second Medical Center of Chinese PLA General Hospital Detail Findings in Gene Therapy (Mitophagy in Hypertensive Cardiac Hypertrophy: Mechanisms and Therapeutic Implications). Cardiovascular Week. September 1, 2025; p 180.
• Tidhar D, et al. Hypertension: a review of the pathophysiology. Nat Rev Cardiol. 2018;15(3):141-151.
• Ling Y, et al. Mitophagy in the heart: a therapeutic target for hypertensive heart disease. Circulation. 2019;139(16):1823-1835.
• Cao Y, et al. PINK1/Parkin-mediated mitophagy in hypertensive cardiac hypertrophy. J Mol Cell Cardiol. 2020;144:133-142.